Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus FORBAXIN.
CHLOROMYCETIN vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic